Authorize psilocybin and DMT access
Petitioners ask that psilocybin and N,N‑dimethyltryptamine (DMT) be authorized for physician‑supervised treatment of cluster headaches, and that regulatory pathways (e.g., Section 56 exemptions or Special Access) be created or expanded.
Why we would sign this petition
- Could provide rapid relief for severe cluster headaches: petitioners cite studies and case reports that psilocybin and DMT may abort or prevent attacks with low physiological risk.
- Establishing Section 56 or Special Access pathways would allow physician‑supervised, compassionate use while enabling monitoring and data collection.
- Authorizing treatment where alternatives are limited may reduce acute suffering and the burden on emergency care if therapies prove effective.
Why we wouldn’t sign this petition
- Available evidence is limited to studies and case reports, so clinical benefit, optimal dosing and long‑term safety remain uncertain.
- Legalizing access risks diversion or inconsistent oversight; regulators may face challenges ensuring standardized, safe delivery.
- A better course may be rigorous clinical trials first or investing in other proven treatments and support services.
The summary and both sets of reasons are AI-generated from the petition and given equal weight. Claims are the petitioners’ own; consult the official record for the full text.
Official petition
Petition to the House of Commons in Parliament assembled Cluster headaches are one of the most excruciating conditions known to medicine, sometimes called "suicide headaches" due to the unbearable suffering they inflict; Studies and case reports indicate that the psychedelic compounds psilocybin and DMT can abort or prevent cluster headache attacks with rapid onset and minimal physiological risk; and These substances remain inaccessible to Canadians suffering from cluster headaches, despite their safety profile and lack of viable alternatives. We, the undersigned, citizens and residents of Canada, call upon the Government of Canada to: 1. Draw the attention of the House of Commons to the urgent and ongoing suffering caused by cluster headaches, and the compelling clinical evidence supporting the use of psilocybin and N,N-Dimethyltryptamine (DMT) as potential treatments.to legalize or authorize physician-guided access to psilocybin and N,N-Dimethyltryptamine (DMT) for patients suffering from cluster headaches; and 2. Implement or expand regulatory pathways (such as Section 56 exemptions or Special Access Programs) to allow compassionate medical use of these compounds for this specific condition.
Government response
No government response is available yet.